Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
NCT04052880
Age 70 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
This is a study for older people who have a certain type of cancer called multiple myeloma. They can't have a transplant. The study will test if a medicine called daratumumab, along with other medicines, can help. The study will watch for any bad side effects and how well the medicine works. The study will keep going until the cancer gets worse, the medicine is too hard on the body, or for other reasons.
This is a study for older people who have a certain type of cancer called multiple myeloma. They can't have a transplant. The study will test if a medicine called daratumumab, along with other medicines, can help. The study will watch for any bad side effects and how well the medicine works. The study will keep going until the cancer gets worse, the medicine is too hard on the body, or for other reasons.
Third Opinion AI Generated Synopsis
Trial Summary
This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confirmed disease progression, discontinuation of study treatment due to unacceptable drug toxicity, or other reasons. Throughout the study, subjects will be monitored closely for adverse events, laboratory abnormalities, and clinical response.
This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous daratumumab, dose-attenuated bortezomib, revlimid, and dexamethasone until confirmed disease progression, discontinuation of study treatment due to unacceptable drug toxicity, or other reasons. Throughout the study, subjects will be monitored closely for adverse events, laboratory abnormalities, and clinical response.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
